Retinoic acid receptor alpha:Retinoid X receptor alpha heterodimer (RARα:RXRA)

The Retinoic acid receptor alpha:Retinoid X receptor alpha (RARα:RXRA) heterodimer is a ligand-activated transcription factor that plays a pivotal role in mediating the biological effects of retinoids, the active metabolites of vitamin A (UniProt P10276, P19793). As a member of the Type II nuclear receptor family, this heterodimer binds to specific DNA sequences known as retinoic acid response elements (RAREs) to regulate the expression of genes involved in cell differentiation, proliferation, and embryonic development (PubMed 9154799). In its unliganded state, the complex recruits corepressors to maintain transcriptional silencing; however, the binding of agonists like all-trans retinoic acid (ATRA) induces a conformational change that recruits coactivators and initiates gene transcription (PubMed 1551). This molecular switch is critical in hematopoiesis, and its disruption—most notably by the PML-RARA fusion protein—is the hallmark of acute promyelocytic leukemia (APL) (NIH/StatPearls). Therapeutic targeting of the RARα:RXRA heterodimer with high-dose retinoids is a cornerstone of APL treatment, effectively inducing the terminal differentiation of malignant promyelocytes. Beyond oncology, the heterodimer is a target in dermatology for conditions like acne and psoriasis, as well as in metabolic research due to its role in lipid and glucose homeostasis (Frontiers in Pharmacology). Despite its therapeutic utility, drugs targeting this complex carry significant risks, including severe teratogenicity and the potentially fatal differentiation syndrome (StatPearls).

Other names

RAR-alpha/RXR-alpha complexRARA:RXRA heterodimerRetinoic acid receptor alpha/Retinoid X receptor alpha complexNR1B1:NR2B1 heterodimerRARα/RXRα heterodimer

The RARα:RXRA heterodimer functions as a ligand-dependent transcriptional regulator. In the absence of a ligand, it binds to retinoic acid response elements (RAREs) in target gene promoters and recruits corepressor complexes (e.g., NCoR, SMRT) and histone deacetylases (HDACs) to repress transcription. Upon binding of an agonist (e.g., all-trans retinoic acid), the receptor undergoes a conformational change that triggers the release of corepressors and the recruitment of coactivator complexes (e.g., SRC-1, p300/CBP) with histone acetyltransferase activity. This remodeling of chromatin leads to the activation of gene transcription, promoting processes such as myeloid differentiation and cell cycle arrest.